Ocumension Therapeutics shifts HK$102.5 million IPO proceeds to working capital, general corporate uses

• Ocumension shifted capital planning toward broader commercial operations, reallocating remaining IPO funds to working capital and general corporate purposes.
• HK$ 102.5 million of unutilized IPO proceeds to be redirected; full use targeted by end-2027.
• Remaining placing proceeds of HK$ 19.37 million also reassigned to working capital and general corporate purposes; full use targeted by end-2027.
• Strategy reflects lower expected spend on OT-401 and OT-1001, with funding needs moving to commercialization support and corporate liquidity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocumension Therapeutics published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260828-12306944), on August 28, 2026, and is solely responsible for the information contained therein.